近視性脈絡網膜萎縮症患者を対象としたPAL-222の第I/IIa相臨床試験
The goal of this clinical trial is to assess efficacy and safety in patients with myopic chorioretinal atrophy.
The main question it aims to answer are:
• Percentage of changes in the chorioretinal atrophic area
Participants will be implanted one sheet of PAL-222 into the subretinal space through pars plana vitrectomy.
Researchers will compare non-therapeutic eye to see if the changes is significant different.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Ube、日本
- Yamguchi University Hospital
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本
- Nagoya city university hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients aged 20 years or older at the time of consent acquisition
- Patients with binocular intensity myopia (myopia of -6.0 diopter (D) or more) or patients with axial length (26 mm) or more equivalent to -6.0 D
- Corrected characters of the test eye patients with visual acuity of less than 60 characters (equivalent to decimal visual acuity 0.32)
- Patients diagnosed with binocular myopic chorioretinal atrophy and having atrophy of 1 papillary diameter (1.5 mm) or more in the area within 2 papillary diameter (3.0 mm) including the fovea centralis in the subject eye
- Patients without active choroidal neovascularization
Exclusion Criteria:
- Patients with abnormal findings that pose a problem in clinical trial participation in screening tests.
- Patients with positive hepatitis B surface (HBs) antigen, Hepatitis C virus (HCV) antibody, Human immunodeficiency virus (HIV) antibody, Human T-lymphotropic virus type 1 (HTLV-1) antibody, syphilis serum reaction
- Patients with allergies to human serum albumin antibiotics, trypsin
- Patients with eye infections
- Patients with other retinal diseases (diabetic retinopathy, hypertensive retinopathy, vascular occlusion)
- Patients with confirmed optic nerve atrophy
- Patients with glaucoma who cannot control intraocular pressure
- Patients with findings associated with myopic traction macular disease (apparent posterior macular tumor, vitreous macular traction, retinal separation, macular hole detachment, macular hole)
- Patients with atrophy in all areas of the circle within 3 papilla diameter (4.5 mm) (9.0 mm in diameter) from the fovea
- Patients with corrected visual acuity of control eye 0.08 or less
- Patients with severe blood disorders, heart failure, liver disorders, and renal disorders
- Patients diagnosed with malignant tumor within 5 years or patients requiring treatment
- Pregnant women, lactating women, patients wishing to become pregnant during the trial period
- Patients who cannot discontinue anticoagulants or antiplatelet drugs before the trial
- Patients with drug addiction or alcoholism
- Patients receiving treatment with vascular endothelial growth factor inhibitor or photodynamic therapy within 4 months prior to transplantation for test eye or 2 months for reference eye.
- Patients who underwent eye surgery (excluding lens reconstruction) within 3 months before transplantation. In the case of cataract surgery, if 7 days or more have passed since surgery and postoperative inflammation is stable, registration is possible.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:治療グループ
|
One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of changes in the chorioretinal atrophic area
時間枠:Just before transplantation,after 3days and 1,2,4,8,12,16,20,24,32,40,52,60,72,84,96-104weeks
|
Assesment by the principal investigator or sub-investigator will be conducted and central committee will adjudicate the assessment. |
Just before transplantation,after 3days and 1,2,4,8,12,16,20,24,32,40,52,60,72,84,96-104weeks
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Hitoshi Kusano, M.D.、PhamaBio Coorporation
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。